# Oral VK2735 and the SUNRISE trials Canonical: https://europeanpeptideshop.com/blog/oral-vk2735-sunrise-phase-3/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Research news · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page Oral VK2735 is Viking Therapeutics' investigational tablet formulation of a GLP-1/GIP receptor agonist. Viking announced its SUNRISE Phase 3 program on October 14 and discussed it again on October 28. A Phase 3 program announcement describes a development milestone, not an approved product or a completed efficacy result. [1](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity) [2](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update) ## What are SUNRISE-1 and SUNRISE-2? Viking describes two randomized, double-blind, placebo-controlled trials with 68 weeks of treatment and planned enrollment of 560 participants each. SUNRISE-1 concerns adults with obesity or qualifying overweight without type 2 diabetes; SUNRISE-2 concerns people with type 2 diabetes. [1](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity) Program | Formulation and question SUNRISE | Oral VK2735; weight-management trials over 68 weeks VANQUISH | Subcutaneous VK2735; a separate Phase 3 program Maintenance studies | Separate studies of maintaining prior weight reduction [1](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity) [2](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update) ## What does the registry currently show? The SUNRISE-1 record, NCT07868835, lists planned enrollment of 560 and percentage weight change at week 68 as its primary outcome. The snapshot checked on November 5 was last posted October 16 and still marked not yet recruiting, with an estimated November start. [3](https://clinicaltrials.gov/study/NCT07868835) That differs in wording from the sponsor's later description of the program as underway. A trial-program announcement and a site's recruitment status are different records. The dated registry should be checked directly before making a claim about enrollment or participation. ## Are the earlier oral results the Phase 3 results? No. The October announcements summarize earlier oral VENTURE research while introducing SUNRISE. Results from a shorter prior-phase study do not become Phase 3 outcomes when a later trial begins. [1](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity) [2](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update) Keep the trial name beside any reported weight-change percentage. Then check whether the source describes oral or injectable material, the follow-up duration, the comparator and the population. This prevents results from different parts of the same development program being combined into an inaccurate headline. ## Is the oral maintenance study a weekly pill study? Viking's October 14 release contains a correction to its October 6 maintenance announcement: the oral maintenance option being evaluated is daily, not weekly. The correction concerns the study description, not instructions for using an available medicine. [1](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity) That correction is a good reason to use the current issuer release instead of repeating an older summary. Maintenance after prior weight reduction is also a different research question from weight reduction measured from the start of a treatment trial. ## What should the next update establish? The useful next evidence is actual Phase 3 reporting, including participant flow, prespecified endpoints, adverse events, discontinuations and the analysis population. Regulatory status must be established separately from clinical results. VK2735's oral and injectable programs share a compound name, but each formulation and study needs its own evidence. This report does not describe a product available for prescribing or suggest that a laboratory material is equivalent to a trial tablet. ## Scope for European readers This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [Viking: oral SUNRISE program announcement, October 14, 2026](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity) - [Viking: corporate and pipeline update, October 28, 2026](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update) - [ClinicalTrials.gov: SUNRISE-1, NCT07868835](https://clinicaltrials.gov/study/NCT07868835) ## More articles Research news · 3 min read ## [Oral semaglutide: the US changes](https://europeanpeptideshop.com/blog/oral-ozempic-semaglutide-pill-rybelsus-wegovy/) Is oral Ozempic available? Compare Ozempic tablets, Rybelsus and Wegovy pill, their US indications, formulation differences and the 2026 name change. 8 November 2026 Compound research · 3 min read ## [Retatrutide side effects in trials](https://europeanpeptideshop.com/blog/retatrutide-side-effects/) Which adverse events were reported in published retatrutide trials, how often, and what those trials can and cannot tell you. 8 November 2026 Research news · 2 min read ## [Australia's Synedica peptide warning](https://europeanpeptideshop.com/blog/synedica-tga-warning-australia-tb-500/) Australian testing found Synedica peptide products contained no TB-500 and less retatrutide than labelled. The TGA has told Australians to discard them. 8 November 2026